

GENE CLUSTER

BACKGROUND OF THE INVENTION

5 Polyketides constitute a large and highly diverse group of secondary metabolites synthesized by bacteria, fungi and plants, with a broad range of biological activities and medical applications. They include anti-cancer agents (Daunorubicin), antibiotics (tetracyclines, erythromycin etc.), immunosuppressants (macrolide FK506) and compounds with mycotoxic activity (aflatoxins, ochratoxins, ergochromes, patulin etc.). Polyketides are synthesized by repetitive condensations of acetate or propionate monomers in a similar way to that of fatty acid biosynthesis. Structural diversity of polyketides is achieved through different thioester primers, varying chain extension units used by the polyketide synthases (PKSs), and variations in the stereochemistry and the degree of reduction of intermediates. Diversity is also achieved by subsequent processing, such as alkylations, oxidations, O-methylations, glycosylations and cyclizations. Genetic studies indicated that gene organization of functional units and motif patterns of various PKSs are similar. This similarity was used to identify and obtain new PKS systems in both gram negative and gram positive bacteria.

20

PKS systems are classified into two types: type I PKSs are large, multifunctional enzymes, containing a separate site for each condensation or modification step. These represent "modular PKSs" in which the functional domains

encoded by the DNA sequence are usually ordered parallel to the sequence of reactions carried out on the growing polyketide chain. Type II PKSs are systems made up of individual enzymes, in which each catalytic site is used repeatedly during the biosynthetic process.

5

Genetic studies on prokaryotic PKSs have focused on gram positive microorganisms, particularly on actinomycetes. Myxobacteria are gram negative bacteria that produce a large number of secondary metabolites, including polyketides. *Myxococcus xanthus* produces TA (Rosenberg, et al., 1973; Rosenberg, et al., 1984), which is an antibacterial antibiotic.

10

The polyketide antibiotic Tel-Aviv (hereinafter TA) (Rosenberg, et al., 1973) is synthesized by the gram negative bacterium *Myxococcus xanthus* in a unique multi-step process incorporating a glycine molecule into the polyketide carbon chain, which is elongated through the condensation of 11 acetate molecules by a type I polyketide synthase (PKSs).

15

The antibiotic TA was crystallized and its chemical properties were determined. It is a macrocyclic polyketide synthesized through the incorporation of acetate, methionine, and glycine. It inhibits cell wall synthesis by interfering with the polymerization of the lipid-disaccharide-pentapeptide and its ability to adhere avidly to tissues and inorganic surfaces makes it potentially useful in a wide range of clinical applications, such as treating gingivitis.

20

A growing interest in the study of PKS systems and peptide synthetase systems stems from the need to develop new potent biologically active compounds. The use of combinatorial genetics in both systems (PKS and peptide synthetase) separately has led to the production of new polyketides and new peptides.

5

It would therefore be useful to be able to generate new biological agents from secondary metabolites of the antibiotic TA.

SUMMARY OF THE INVENTION

10

According to the present invention, there is provided a purified, isolated and cloned DNA sequence partially encoding a functional portion of a polypeptide component required for the synthesis of antibiotic TA. Also provided are purified, isolated and cloned DNA sequences encoding a polypeptide component required for postmodification of antibiotic TA and encoding a gene product involved in the regulation of the biosynthesis of antibiotic TA. A purified, isolated and cloned DNA sequence having a DNA sequence (Seq. ID No. ~~1~~ and 2) encoding a polypeptide component required for encoding the TA gene cluster and any mutations thereof is provided. Also provided are methods of using the TA genes for combinatorial genetics and of using the TA genes encoding for synthesis and modification or regulation of antibiotic TA.

20

DESCRIPTION OF THE DRAWING

Other advantages of the present invention will be readily appreciated as the same becomes better understood by reference to the following detailed description
 5 when considered in connection with the accompanying drawing wherein:

Figure 1 shows the physical maps of the DNA regions involved in TA synthesis.

DETAILED DESCRIPTION OF THE INVENTION

10 *a* The present invention consists of a DNA ^{and amino acid} sequence of at least 42 kb encoding genes involved in TA production and *Myxococcus xanthus* as best shown in Seq. ID No:1 through 17 and cosmid clones containing the entire TA gene DNA sequences.

15 The TA gene cluster has been purified, isolated, and cloned. The purification, isolation and cloning was done according to the methods described in Marshak et al, "Strategies for Protein Purification and Characterization. A laboratory course manual." CSHL Press, 1996.

20 A DNA fragment of at least 42 kb (Figure 1), encoding genes involved in TA production in *Myxococcus xanthus* has been identified, cloned and analyzed. These steps were done in accordance with Marshak et al, "Strategies for Protein Purification and Characterization. A laboratory course manual." CSHL Press, 1996. This

fragment contains a large region of about 20 kb, encoding the genes responsible for the regulation and the post-modification of TA. An additional fragment of approximately 8-10 kb located 10-20 kb downstream of the post-modification region, encodes the enzyme responsible for the incorporation of the glycine into the polyketide chain. This novel polypeptide is made up of a peptide synthetase unit
5 lying between two PKS modules.

The potential of this unique polypeptide in combining the two systems can lead to a new family of compounds, emerging from various combinations which can
10 be utilized for combinatorial genetics. Such utilization can produce, for example, new bioactive agents, new polyketides and new peptides. Additionally, the TA gene cluster can be utilized in a method for the synthesis, modification or regulation of the TA antibiotic.

15 Mutations imparting defects into the TA gene cluster can be point mutations, deletions or insertions. The mutations can occur within the nucleotide sequence of the allele of the TA gene cluster such that the resulting amino acid sequence of the TA gene cluster product is altered.

20 In one embodiment of the present invention, the TA gene cluster can be included in a vector or recombinant expression vector. This vector containing the TA gene cluster is able to transform a suitable eucaryotic or procaryotic host cell. A suitable host cell can be determined by one skilled in the art. An example of a

suitable cell which can be transformed by the TA gene cluster is an E. coli cell.

In another embodiment of the present invention, the a DNA fragment encoding the TA gene cluster can be cloned into a cosmid, as shown in Figure 1. This DNA
5 fragment contains a large region of about 20kb, encoding the genes responsible for the regulation and the post-modification of TA. An additional fragment of approximately eight to ten kb is located 10-20 kb downstream of the post-modification region and encodes the enzyme responsible for the incorporation of the glycine into the polyketide chain. The novel polyketide chain is made up of a peptide synthetase unit
10 lying between two PKS modules (See Figure 1).

The above discussion provides a factual basis for the use of the TA gene cluster. The methods used with and the utility of the present invention can be shown by the following non-limiting examples and accompanying figure.

EXAMPLES

GENERAL METHODS:

METHODS:

General methods in molecular biology: Standard molecular biology
20 techniques known in the art and not specifically described are generally followed as in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Springs Harbor Laboratory, New York (1989, 1992), and in Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley and Sons, Baltimore, Maryland (1989). Polymerase

chain reaction (PCR) is carried out generally as in *PCR Protocols: A Guide To Methods And Applications*, Academic Press, San Diego, CA (1990). Reactions and manipulations involving other nucleic acid techniques, unless stated otherwise, are performed as generally described in Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, and methodology as set forth in United States patents 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057 and incorporated herein by reference. In-situ (In-cell) PCR in combination with Flow Cytometry can be used for detection of cells containing specific DNA and mRNA sequences (Testoni et al, 1996, Blood 87:3822.)

Recombinant Protein Purification

Marshak et al, "Strategies for Protein Purification and Characterization. A laboratory course manual." CSHL Press, 1996.

Example 1:

Analysis of the TA gene cluster by chromosomal restriction map.

Chromosomal DNA of several transposition mutants (ER-2514, ER-1037, ER-1030, ER-1311, ER-7513, ER-3708, ER-4639 and ER-6199; Varon *et al.*, 1992) was extracted, digested with restriction enzymes that cut within the transposon, and analyzed by Southern hybridization with six different probes (originating from TnV and Tn5*lac*). We used probes designed to hybridize either to the entire transposon, or to its 5' or 3' ends. A chromosomal restriction map of the whole gene cluster was constructed on the basis of these results (Figure 1). The data refined the transduction

map (Varon *et al.*, 1992) and further indicated that all the genes in the cluster are transcribed in the same direction (see Figure 1).

Preparation of TA-specific probes

DNA from the TnV mutant ER-4639, ER1311 and ER-6199 was digested with *KpnI* (does not restrict TnV), self-ligated and transformed into *E. coli* XL1-Blue MR using the transposon-derived kanamycin resistance for selection. Transformant clones pPYT4639, pPYT1311/p5 and pPYT6199 carried a 1.5 kb, 2.3 kb and a 11.2 kb fragment, respectively (see Figure 1).

Cloning of a *M. xanthus* DNA region encoding genes involved in TA biosynthesis.

A library of *M. xanthus* ER-15 was constructed in the cosmid vector SUPERCOS-1 and screened using specific TA probes obtained from transposition mutants (ER-4639, ER-1311 and ER-6199, see map) that contain a TnV transposon. Seventy four recombinant cosmids that carried genes required for TA production were identified through colony hybridization. The cosmids, pPYCC64 and pPYCC44, which hybridized to these probes were further characterized through restriction analysis (see Figure 1) and sub cloned for sequencing.

Throughout this application, various publications, including United States patents, are referenced by author and year and patents by number. Full citations for the publications are listed below. The disclosures of these publications and patents in

The invention has been described in an illustrative manner, and it is to be understood that the terminology which has been used is intended to be in the nature of words of description rather than of limitation.

10

REFERENCES

1. Rosenberg, E., Vaks, B. and Zuckerberg, A. Bactericidal action of an antibiotic produced by *Myxococcus xanthus*. *Antimicrob. Agents. Chemother.* 4:507-513 (1973).
2. Rosenberg, E., Porter, J.M., Nathan, P.N., Manor, A. and Varon, M. Antibiotic TA: an adherent antibiotic. *Bio/Technology.* 2:796-799 (1984).
3. Varon *et al.*, 1992
4. Marshak et al, "Strategies for Protein Purification and Characterization. A laboratory course manual." CSHL Press, 1996.
5. Testoni et al, 1996, *Blood* 87:3822.
6. *PCR Protocols: A Guide To Methods And Applications*, Academic Press, San Diego, CA (1990).
7. Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Springs Harbor Laboratory, New York (1989, 1992).
8. Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley and Sons, Baltimore, Maryland (1989).

SEQ LISTING PAGE(s)

REGION 1:Ta1 - Pentidesynthetase unit-PKS module.FRAGMENT size(aa):2392

VDPARLTRAWEGLLERYPLLGAIRVEGETEPIVPSGQVSAEVHEVPSVSDSALVATLRASAKVPFDLAC
 GPLARLHLYSRSEHEHVLLLCFHHLVLDGASVAPLLDALRERYAGTEAKAGLLEVPIVAPYRAAVEWEQ
 LAIGGDEGRRLDYWRHVLATPVPPPLNLPDRPRSATGLDSEGATHSQRVPTEQALRLREFARAQQVS
 LPTVLLGLYYALLHRTRODDVVVGIPMTGRPRAELATAIGYFVNVMAVRARGLGQHSFGSLLRHLHDS
 VIDGLEHAHYFFPRVVKDARLSNGPEEAPGFQTMFTFQSLQLTSAPPRPEPRSGGLPELEPLDCVHQEGAY
 PLELEVVEGAKGLTLHFKYDARLYEADTVERMARQLLRAADQVADGVESPLSALSWLDDEERTLLRD
 WNATATPFLEDLGVHELFOQARETPDAMAVSYEGHSLSYQALDTRSREIAAHLKSFGVKPGALVGIYL
 DRSAELVAAMLGVLSAGAAVPLDPVHPEDRLRYMLEDSGVVVVLARQASRDKVAALAGASCKVCVLE
 DVKAGATSAPAGTSPNGLAYTYTSGSTGRPKGVMPHRGVVNFLLCMRRILGLKRIDSLLAVTTYCFD
 IAALELLLPLCAGAQVILASAEVVRDAQALKRALRTHRPTLMQATPATWTLLFQSGWENAERVRLCGGE
 ALPESLKAHFVRTASDVWNMFPTETIWTSTMAKVSASRPVTIGKPIDNTQVYVLDLDRMQPVPFVGPGE
 LWIAGAGVACGYLNRPALTAERFVSNPFTPGTTLTYRTGDLARWRADGEVEYLGRLDHQVKVRGFRIEM
 GEIEAQLAGHPSVKNCVVAKEINGTSQLVAYCQAGTSFDEEAIRAHRLKFLPDYMPAHVFAVDAIP
 LSGNGKVDRGQLMARPVVTRRKTSVHARSPEATLVELWKNVLQVNEVGVEDRFFEVGGDSVLAHV
 LVEEMNRRFDTRLAVTDLFKYVNRDMARHMEGATAQARTGATEPARED TASERDYEGLAVIGISCQL
 PGAADPWRFWKNLREGDSVVA YRHEELRELGVPEEVLDRSRYVAVRSSIEDKECFDPHFFGLTARDAS
 FMDPQFRLLLMHAWKAVEDAATTIERLGPCGVFMTASNSFYHQGSPQFPADGQFVLRTAEYVVLWVLA
 QAGSIPTMVSYKLGKGPSLFFVHTNCSLSALYVAQQAALAGDCQTALVGAATVFPANLGYLHQGL
 NFSSAGR VKAFDAADGMIAEGVA VL VVKDAAA AVR DGDPIYCLVRKVGINNDGQDKVGLYAPSAT
 GQAEVIRRLFDRTGIDPASIGYVEAHGTGTLGDPVEVSALSEAFRTFTDRRGYCRLGSVKSNLGHLDTV
 AGLAGLIKTA LSLRQGEVPPTLHVTQVNPKELELTDSPFVIADRLAPWPSLPGRRAAVSAFGLGGTNTHAI
 LEHYPRDSRPRERSQRSNA VRAVAPFSARTLEALKDNLRALLDLFEDFASAEVALADITYTLQVGRVAMP
 ERMVVTASTRDELVEGLRRGIATVGGAHVGTVDTSVSDADARAVAEAWATGDSIDWDSLHGDVKP
 ARVSLPTYQFAKERYGLSPAHSVANSSKTHPDAGVPLFVPTWQPWSEGASNASLALRHLVVLCEPLDAL
 GAEGASALASTLADRRIEVVRTSSPSARLDARFMAHASAVFERVKALLSERLTAPVTQLQVLVPEERDALA
 LSGLGSLRLSVSQENPLVRGQLRVQGSVSASALVDVLYKSARAGDVTD SRYIAGQLSRCEWREARVAK
 GDASRFWREDGVYVISGGTGALARLFVAEIGKRATRATVILVARASSAEAVDGGNGLRVRHLPVDVTQP
 NDVNAFVATVLRHGRIDGVTHAAGIRRDNYLLNKPVAEMQAVLAPKVVGVLVNLDHATRELPLDFFVTF
 SSLAAGNAGQSDYAAANGFMDGFAESRAALVNAGQRQGRTVSIRWPLWENGGMQLDSRSREVL MQR
 TGMAALGDEAGLGAFYRALELGSPGVAVVTGEAQRFRELSVSVSPAPPPHQVALDAVVSITEKVETKLK
 ALFSEVTRYEERRIDARQPMERYGIDSIITQMINQALEGPYNALSKTLFFEYRTLAEVSGYLAEHRAEESA
 KWVAAPGENSSSVIQEARPPRADA THRAPRADIPIAVIGMSGRYPGAENLTFWERLSRGDDCITEIPPER
 WSLDGFYFPDKKHAAARGMSYSKWGGFLGGFADFDFLFFNISPREATSM DPQERLFLQSCWEVLEDAG
 YTRDSL AQRFGSA VGVFAGITKTGYELYGAELQRDASVRPYTSFASVANRVSYLLDLKGPSMPVDTC
 SASLTAVHMACEALQRGACVMALAGGVNLYVHSSYVSLSGQQMLS

DNA sequence nucleotides 1-7178.

GTCGACCCGGCGAGGCTGACCCGGGCCTGGGAAGGACTGCTCGAACGGTATCCGCTGCTCGCTGGC
 GCGATTTCGCGTCGAAGGCACGGAGCCGTCATCGTCCCCAGTGGGCAGGTCTCCGCCGAGGTCCAC
 GAGGTTCCATCGGTCTCCGATTACGCACTGGTGGCGACCCTGCGCGCCTCCGCGAAGGTGCCATTCCG
 ATCTCGCCTGTGGACCCGCTCGCTCGGCTGCACCTGTACTCGCGGTCGGAGCACGAGCATGTCTGCT
 GCTGTGCTTCCACCACCTGGTGCTCGATGGGGCATCCGTGGCGCCCTTGCTCGACGCCCTCCGGGAG
 CGTTACGCCGGGACCGAGGCGAAGGCGGGGCTGCTCGAGGTTCCGATCGTCTGCTCCTTACCGCGCC
 GCCGTGGAGTGGGAGCAGCTCGCCATTGGAGGCGATGAGGGACGGCGCCACCTCGACTACTGGCGG
 CACGTGTTGGCCACGCCCTTCTCTCCGCCGTTGAATCTTCCAACGGACCGGCCCTCGCTCCGCCACGG
 GGCTGGACTCGGAGGGAGCAACGCACTCGCAGAGGGTGCCACCCGAGCAAGCATTGCGACTGCGCG
 AGTTCGCTCGGGCACAGCAAGTGAGCCTGCCGACCGTCTGCTCGGGCTCTACTACGCCCTTGCTTCA
 TCGGCACACGCCCCAGGACGACGTGGTGGTGGGCATCCCCACCATGGGGCGGGCCCCGGGCGGA
 GCGGACGGCGATTGGGTACTTGTCAACGTGATGGCCGTGCGCGCGGGGCTGGGGCAGCACT
 GTTCGGCTCGCTGCTGCGCCACCTCCACGACTCGGTTCATCGATGGCCTGGAGCATGCCACTATCCC
 TTCCCGCGAGTGGTGAAGGACCTCCGGCTGTGCAATGGGCCCGAGGAGGCGCCTGGCTTCCAGACG
 ATGTTACCTTCCAGAGCCTGCAATGACGAGCGCTCCGCCAAGGCCGGAGGCCAGGTGGGGCGGG
 TTGCCGGAGCTTGAGCCGCTCGACTGCGTCCATCAGGAAGGCGCCTACCCGCTGGAGCTTGAAGTGG
 TGGAGGGCGCCAAAGGGCCTCACGCTGCATTTCAGTACGACGCGCGGCTGTACGAGGCGGACACGG
 TCGAACCGATGGCGCGTCAGTTGTTGCGCGCCGCGGACCGAGTGGCGGATGGGGTGGAGTCTCCGC
 TGAGCGCACTGCTCGTGGCTCGACGACCAAGAGCGCCGACGCTTCTCCGCGACTGGAATGCCACGG
 CCACGCGCTTCTCGAGGACCTGGGCGTTACGAGCTCTTCCAGCGGCAGGCCCGGGAGACCCAG
 ACGCCATGGCTGTGAGCTACGAGGGGCACTCGCTCAGCTATCAGGCGCTGGATACGCGGAGCCGCG
 AGATTGCGGCGCACCTGAAGAGCTTCCGGGTCAAGCCTGGGGCGCTCGTGGGCATCTACCTGGACC
 GGTCCGCGGAGCTGGTGGCGGCGATGCTGGGTGTGCTGTCCGCTGGCGCGGCTACGTACCCCTGG
 ACCCGGTGCACCCCGAGGACCGGCTGCGGTACATGCTGGAGGACAGTGGCGTGGTGGTGGTGGTGG
 CCCGTACGGCCTCGCGGGACAAGGTGCGCGCATTGCCGGAGCCTCCTGCAAGGTGTGCGTGGTGG
 AGGACGTCAAGGCTGGAGCCACGTCCGCGCGCGCGGGAACCTCACCGAACGGACTTGCTACGTCA
 TCTACACGTCCGGGAGCACGGGCCGCGCCCAAGGGCGTGATGATTCCCCATCGCGGGGTGGTCAACT
 TCCTCCTGTGATGCGCAGGACGCTGGGCCTGAAGCGCACGGATTGCTGTGGCGGTACACGACGTA
 CTGCTTCGACATCGCGGCGCTCGAGCTCCTGCTTCCGCTGTGTGCGGGGGCGCAGGTATCATCGCG
 TCGGCGGAGACGGTTCCGGGATGCGCAGGCGTTGAAGCGGGCGCTGCGCACCCATCGGGCCACGTTG
 ATGACGGCGACGCCCGGACCTGGACACTGTTGTTCCAGTCTGGCTGGGAGAACGCCGAGCGGGTT
 CGAATCCTCTGCGGTGGAGAAGCGCTGCCGGAGTCTGCTCAAGGCCCACTTCGTTGCGACCGCGAGC
 GACGTGTGGAACATGTTCCGGGCCACCGAGACGACCATCTGGTTCGACGATGGCGAAGGTCTCGGCC
 TCGCGTCCGGTACCATTTGAAAGCCGATCGACAACACCGAGGTCTACGTGCTGGACGACCGGATG
 CAGCCGGTGCCCATCGGTGTGCCGGGCGAGCTGTGGATTGCGGGCGCGGGCGTGGCCTGCGGTTAC
 CTCAACCGGCCGCGCTGACCGCCGAGCGCTTCGTTTCAAATCCGTTACGCCGGGACGACGCTCT
 ACCGGACGGGGACCTGGCGCGCTGGCGCGCTGACGGTGAGGTTGAGTACCTGGGGCGGCTCGACC
 ACCAGGTGAAGGTGCGCGGCTTCCGCATCGAGATGGGGGAGATTGAAGCGCAGTTGGCCGGGCATC
 CCAGCGTGAAGAACTGTGCCGTGGTGGCCAAGGAGCTGAACGGCACCTCGCAGCTCGTCGCTACT
 GTCAGCCCGCGGGAACGAGCTTCGATGAGGAAGCCATCCGTGCACACCTGCGGAAGTTCCTCCCCG
 ACTACATGGTCCCCGCGCACGTCTTCGCGGTGGATGCGATTCCGCTGTGCGGCAATGGCAAGGTGGA
 CCGGGGCCAGCTGATGGCCAGGCCGGTGGTCAACCGGCGGAAGACATCCGCGGTCCATGCCCGTTC
 GCCTGTTGAGGCCACCTCGTCGAGCTGTGGAAGAAGCTGCTCCAGGTCAACGAGGTGGGTGTGCA

000111 29201260

Sub
 B1
 cont

GGATCGCTTCTCGAAGTGGGGGGGACTCCGTGCTGGCCGCCGTGCTGGTGGAGGAGATGAACCG
 GCGCTTCGACAGCGGGCTCGCCGTACCGACCTGTTCAAGTACGTCAATATTCGCGACATGGCGCGC
 CACATGGAGGGGCGGACGGCGCAAGCCCGTACTGGGGCCACCGAGCCGGCTCGCGAGGACACCGCG
 TCGGAGCGTGACTACGAGGGCAGCCTGGCCGTATCGGCATCTCCTGTAGTTGCCCGGAGCCGCG
 ACCCTGGCGCTTCTGGAAGAACCTGCGAGAGGGCAGGGACAGCGTGGTGGCGTACCGCCATGAGG
 AACTGCGCGAGCTGGCGGTGCCCGAGGAGGTCTCCCGGATTCCCGTTACGTGCGCGGTCCGGTCTGTC
 CATCGAAGACAAGGAGTGCTTCGACCCGCAATTCTTCGGTCTGACGGCGCGGGACCGGTCTCTCATG
 GACCCGCGAGTTCCGACTGTTGCTGATGCACGCCCTGGAAGCTGGAAGACGCGGCGACGACGCCT
 GAGCGCCTGGGACCGTCCGGCGTCTTCATGACGGCCAGCAACAGCTTCTATCACCAGGGCTCGCCGC
 AATTTCTGCGGACGGGCGAGCCGTCTCCGACCCGCCGAAGAATACGTGCTGTGGGTGCTGGCCCA
 GGCAGGCTCCATCCCGACGATGGTTTCTSTACAAGCTCGGCTTGAAGGGGCCGAGCCTGTTCTGTCAC
 ACCAAGTGTCTGTCATCCCTGTCCGCGCTGTACGTGGCTCAGCAGGCCATCGCAGCGGGAGACTGCC
 AGACGGCGCTGGTGGGGGCGCCACGGTCTTCCCTTCGGCGAAGTTGGGTATCTGCACCAGCGGG
 GGCTCAACTTCTCCAGCGCGGGCGGTCAAGGCCTTCGACGGCGCGGCGGACCGCATGATTGCCG
 GTGAAGGTGTGCGCGTGTGTTGGTGAAGGACCGCGGCGGCGGTGCGCATGCGGACCCCAATCT
 ACTGCCTCGTGGCGAAGGTGGGATCAACAACGACGGCCAGGACAAGGTGGGTGAGTGGCGCCCAATCT
 GCGCCACCGGGCAGGCGGAGGTATCCGGCGTCTGTTGACCGGACCGGCATCGAACCTGTCATCGA
 TTGGCTACGTGAGGCCCCATGGGACCGGAACCTTGTGGGTGACCTGTGAGGTCTCCGCGCTGAG
 CGAAGCCTTCGGACCTTACCGGACCGGCGCGGTACTGCCGGCTGGGCTCGGTGAAGTCAACCT
 GGGCCATCTCGACACAGTGGCTGACTGGCTGGGTCTCATCAAGACGGCGCTGAGCCTGCGGCAGGG
 CGAAGTTCCTCCGACGCTCCATGTGACCCAGGTGAATCCGAAGCTCGAGCTGACGGAATTCGCGTTC
 GTCATCGCCGACCGTTTGGCGCCGTGGCGTCCCTGCCGGGACCGGCGGCGCGGTGAGTGGC
 TTCGGCCTTGGCGGGACGAATACCCACGCCATTCTCGAACACTACCCGCGCGACTCCCGCCCCAGGG
 AGAGGAGCCAGCGGTGGAACGCACTGCGGTGGCTCCATTCTCGGCGCGCACCTGGAGGCGT
 TGAAGGACAACCTCCGCGCGCTGCTGACTTCTGAGGACCCGGCGTCCGCGGAGGTGGCGCTCG
 CGGACATCACTACACGTTGACGTTGCGCGGTGCGGATGCGTGAAGTGGTGGTGGTGGTGGTGGT
 CGACGCGCGACGAATTGGTGGGAGGAGTGGCGGCGGATGCGTGAAGTGGTGGTGGTGGTGGTGGT
 GAACGGT
 CGGGCGACTCGATTGACTGGGATTGCTGACCGGTGACGTGAAGCCCGCCCGTGTGAGCCTGCCAC
 GTATCAGTTCGCGAAGGAGCGCTACGGGTGTCGCGCCGCGCACTCCGTGGCGAAATTCCTCCAAGACG
 CATCTGACGCGGGTGTCCCGCTCTTCGTTCCGACCTGGCAGCCGTGGTCTGAGGGCGCGTCAAATG
 CCTCGTTGGCGCTCGCGCACCTTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT
 CTCGCGCTGGCGAGCACGCTCGCGGACAGGCGATCGAAGTGGTGGTGGTGGTGGTGGTGGTGGTGGT
 GCGGCTGGACGCGCGGTTTCATGGCGCATGCTTGGCGGTCTTCGAACGCGTCAAGCGCTGCTGTGCG
 GAGCGTCTGACCGCTCCTGTGACATTGACGTTGCTGGTGGCAGAGGAGCGGGATGCGCTGCACTG
 AGTGGCCTGGGGAGCCTGCTGCGTTCGGTGTGCGAGGAGAATCCGTGGTCCGGGGGCGAGCTCATC
 CGCTCCAGGGAAGCGTCTCCGCATCGGCGCTGGTGGACGTTCTGGTGAAGTCCGCGCGCGCGCGGT
 GACGTACCGGATTGCGGTTACACGCGGGCCAGCTTCTCGCTGTGAGTGGCGCGAGGACGTTGTCG
 CCAAGGGGGACGCAATCCCGCTTCTGGCGCGAAGACGGCGCTATGTGATTCAGGAGGAACCGGGC
 CCTGGCCCCGCTGTTCTGTCGCGGAAATCGGGAAGCGCGGACCGCGGCAACCGTCTGTTGCG
 CCGCGCATCCTCGGCGGAGGCGGTGGACGGTGGGAACGGGCTGCGCGTGGCGCACCTTCCCGTGG
 TGTACCCAAACCGAACGACGTGAACGCTTGTGCTACGGTGTGCGCGAACACGGGCGCATCGAC
 GGTGTATCCATCGCGCGGGCATCCGCGGTGACAACCTGCTCAACAAGCCGGTGGCGGAAATG
 CAGGCGGTGCTCGCGCCCAAGGTGGGCTCGTCAACCTGGACACGCCACCCGCGAGCTGCCC
 CTGGATTCTTCTGTCACGTTCTCGTCCCTGGCGCGTTTGAAACGCGCGTCACTCGGACTACGCGG
 CGGCCAATGGCTTCAATGGACGATTGCGCGGATCCGCGGATCCGCGGCTGGAACGCGCGACGCGG
 AGGGCCGCGACGGTGTCCATCCGTTGGCGCTCTGGGAGAACGGCGGGATGCAAGCTCAGCTACGGA
 GCCGTGAGGTCTTGATGACGCGGACCGGGATGGCCGCGCTGGGAGACGAAGCGGGACTGGGGGCGT
 TCTACCGGGCGCTGGAAGTGGGCTCCCTGGTGTGCGCGGTGGACGGGGGAGGCCAGAGGTTTC
 GTGAAGTCTCCGTGAGTGTTCGCCCCGACCGCTCCGCAATCAGGTGGCGTTGGACCGCGTGGTGTG
 CATCACCGAGAAGGTGAGACGAAGCTGAAGCGCTCTTCAACGAGGTACGCGATACGAAGAGCG
 CCGCATCGATGCCCCGCCAGCGGATGGAGCGCTATGGCATCGACTCCATCATCAGCGAGATGAAC
 CAAGCCCTCGAAGGGCCGTACAACGCCCTCTCGAAGACGCTGTCTTCGAATACCGGACGCTCGCG
 AAGTCAGCGGGTATCTGGCCGAGCACCGCGCGGAAGAGAGCGCGAAGTGGGTGGCGGCACCTGGA
 GAGAATTCGTCTTCGTCATCCAGGAGGCCAGGCCGCCACGTGCGGATGCGACGACCGGGCGCCT
 CGCGCGGAGCGCCATCGCCGTCAATTGGCATGAGCGGCCGTTATCCCGGGGCGGAGAACCTGACG
 GAGTCTGCGGAGCGCGTGGACGCTGACGACTGCATCACCAGATTCCGCCAGAGCGCTGGTGG
 TTGGACGGGTTCTTCTACCCGGACAAGAAGACCGCGCGCGGGGATGAGCTACAGCAAGTGG
 GGCGGCTTCTCGCGCGCTTCTGCTGACTTCGACCCGCTGTTCTTCAACATCTCGCGCGTGGAGCG
 CGAGCATGGACCCGCGAGGAGCGCTTGTCTGTCAGAGCTGCTGGGAGGTCTGGAGGACGCGGGGT
 ACACCCGCGACAGCCTGGCCAGCGCTTGGGAGCGCGGTGGGCGTTTCGCGGGAATCACGAAGA
 CGGCTACGAATCTACGCGCGGAGCTGGAAGGACGAGATGCCTCGCTCCGGCCCTATACGTGCT
 TTGCGTCTGTGTTCAACCGCGTCTGATCTGCTCGACCTGAAGGGGGCGAGCATGCCCGTGGACAC
 CATGTGCTCGGCTCGCTGACAGCCGTCCACATGGCTTGGAGGCGCTGCAACGAGGCGCTGCGTC

000111 292075

Sub
B1
Cmr

2290.00075

ATGGCCATCGCGGGTGGAGTGAATCTCTACGTCCACCCGTCGAGCTACGTCAGCCTGTCCGGGCAGC
AGATGCTGTTCGAC

REGION 2

TaR1 - Surface layer protein

From nucleotide 2955 to 601, size(aa): 785.

MKVVNKLEKLPDVVAGKVPDVKLQDQDIKVPLAQQGTFTTEKILPPKLAMHGFSLFEATGEASIRNFNS
LGDVDENGIGEPSESAEPGPRPQLLLGSDIGWMRYQVSARVKAASVSASLSFLASENQTELSVTLSDYRA
HPLGQNMREAVRSDLSELRLMQATDLAKLTGDAVAWHVRGALHTRLELNWADIFFTNLNLGFLRGN
ELLALKTSAGLSARVSLTDDYQLSFSRPRAGRIQVAVRKVKSHEQALSAGLGITVELLDPATVKAQLG
QLLEALLGPVLRDLVKKGTAVEIMDGLVDKASKAKLDDNQKKVLGLVLERLGIDPQLADPANLPQAW
ADFKARVAESLENAVRTQVAEGFEYEYLRLESETSTLLEVVEDVTAMRFHESLLKGNLVELLKWMKSLP
AQQSEFELRNYLHATTLTRQQAIGFSLGLGSFELLKAKNVSKQSWVTQENFQAGARRMAFLGRGYEDKL
LGTRGQWVVDLKADMTFRFSPTPVASDFGYGLHMLWGRQKKLSRKDLQQA VDDA VVWGVLDAKDA
ATVISTMQEDMGKHPIETRLLEKMADDSFRAVPRIQTLELSRFSRALARALPWSEQLPRASAEFRRAVY
APIWEAYLREVQEQGSLMLNDLSPSRAAQIAKWYFQKDPTVRDLGKDLQLIESEWRPGGGNFSFAEVIS
KNPNTLMRCRNFVSGMVRLRRRAIDERKAPDELRTVFGELEGMWTTGFHLRAAGSLLSDLAQSTPLGLAG
VERTLTVRVADSEEQLVFSTARSTGAA

TaR2 - two component system, response regulator

From nucleotide 3116 to 4702, size(aa): 529.

MPSGCYGAASAFVLPPLPAMPQAPSDVSVQVLLPFGGLVGREVDLDAFLQTLMDRIAITLQADRGTLWLL
DPARRELFSAHLPEVSQIRVKLGQGVAGTVAKAGHAINVPDPRGEQRFFADIDRMTGYRTTSLLAVPL
RDGDGALYGVQLVLRNRGEDRFTDEDTORLTAIASQVSTALQSTSLYQELQRAKEQPQVPVGYFFNRIG
ESPQLQAIYRLVRKAAPTDA TVLLRGESGSGKELFARAVHVNGPRRDQPFKVDCAALPATLIENELFGH
ERGAF TGADHRVPGKFEEAASGGTVFIDEIGELPLPVQGKLLRVIQDREFERVGGTQAVKVDVRIVAATHR
DLARMVAEGRFREDLYYRIKYVEVVLPLRERGAEDIERLARHFVAAVARRHRLTPPRLSAAAVERLKR
YRWPGNVRELENCIESAVVLCEGEILEEHLPLPDVDRAALPPAAAQGVNAPTAPAPLDAGLLPLAEVER
RHILRVLD AVKGNRTAAARVLAIGNRTLARKLKEYGLGDEP

TaR3 - two component system, kinase sensor.

From nucleotide 5595 to 4720, size(aa): 292

MRASQAEAPHSSRLTMEVRFHGVGRGSI VSGSRIGNTACVEVTSQGHRLILDAGTGIRALGEIMMREG
APQEATLFFSHLHWDHVQGFPFFTPAWLPTSELTYGPGANGA QALQSELAAQMQLHFPVPLSTMRSR
MDFRSALHARPVEVGPFRTPIDVPHPGCLAYRLEADGHSFVYATDVEVRVQELAPEVGRLFEAGADVL
CLDAQYTPDEYEGRKGVAKKGWGHSTMMDAAGVAGLVGARRLCLFHHDPAHGDDMLEDMAEQARA
LFPVCEPAREGQRLVLGAA

TaA - NUS-G like transcription antitermination.

From nucleotide 6290 to 6793, size(aa): 168

MPGPRCAENDWVALLVRVNHEKVAAAQLGKHGYEFTLPTYPKSSGVKAKLPLFPGYLFCRYQPLNP
YRIVRAPGVIRLLGGDAGPEAVPAQELEAIRRVADSGVSSNFCDYLRVGQRVRUEGFLTGLEGSLVTSKS
QLRFIVSVGLLQRSVSVEVSAEQLEPID

2290.00875

TaB - acyl carrier protein (ACP).

From nucleotide 6870 to 7106, size(aa): 79

MDKRIIFDIVTSSVREVVPESHPFEPEDDLVGLGANSILDRAEIVNLTLEKLALNIPRVELIDAKTIGGLV
DVLHARL

TaC - beta-ketoacyl [ACP] synthase III (KAS III, FabH)

From nucleotide 7119 to 8378, size(aa): 420

MGPVGIEAMNAYCGIARLDVLQLATHRGLDTSRFANLLMEKTVPLPYEDPVTYGVNAARPILDQLTAA
ERDSIELLVACTESSFDGKAMSTYLHQHLGLSRNCRLLIELKSACYSGVAGLQMAVNFILSGVSPGAKAL
VVASDLRSFSAIEGGDASTEDWSFAEPSSGAGAVAMLVSDTPRVFRVDVGANGYYGYEVMDCRPVAD
SEAGDADLSLLSYLDCCENAFREYTRRVPAANYAESFGYLAFTPFGGMVKGARTMMRKFSGKNRGD
IEADFQRRVAPGLTYCQRVGNIMGATMALSLGTDHGDFA TAKRIGCFSYSGSCSSEFFSGVVTEEGQQ
RQRALGLGEALGRRQQLSMPDYDALLKGNGLVRFGTRNAELDFGVVGSIRPGGWGRPLLFLSAIRDFHR
DYQWIS

TaD - membrane associated protein

From nucleotide 8404 to 9378, size(aa): 325

MSSVATAVPLTARDSAVSRRLRITPSMCGQTSIFAGQIGDWA WDTVSRLCGTDVLTATNASGAPTYLAF
YYFRIRGTPALHPGALRFGDTLDVTSKAYNFGSESVLTVHRICKTAEGGAPEADAFGHEELYEQPQPGRI
YAETFNRWITRSDGKSNESESLKSSPVGFQYAHLLPDEYSPRRAYGDARARGTFHDVDSAERYLTVDRF
PLRYAVDVIRDVNGVGLIYFASYFSMVDVAIWQLARHQGRSEQAFLSRVVLDQQLCFLGNAALDTTFDI
DVQHWERVGGGEELFNVKMRGAQGRDIAVATVKVRFDAASEGGRG

TaE - acyl carrier protein (ACP).

From nucleotide 9386 to 9364, size(aa): 82

MTDEQIRGVVHQSIVRVLPRVRSNELAGHLNLRELGADSVDRVEILTSILDSLRLQKTPLAKFADIRNIDAL
VAFLAGEVAGG

TaF - beta-ketoacyl [ACP] synthase III (KAS III, FabH)

From nucleotide 9757 to 10878, size(aa): 374

MMQERGVALPFEDPVTNAVNAARPILDAMSPEARERIELLVTSSSGVDFSKSISSYAHEHLGLSRHCRFL
EVKQACYAATGALQALGYIASGVSPGAKALVIATDVILVDESGLYSEPAMGTGGVA VLLGDEPRVMK
MDLGAFGNYSYDVFD TARPSPEIDIGDVDRSLFTYLDCLKHSFAAYGRVDGVDFVSTFDYLAHMTFFA
GLVKAGHRKMMRELTPCDVDEIEADFGRRVKPSLQYPSLVGNLCSGSVYLSLCSIDTIK PERSARVGMF
SYSGCSSEFFSGVIGPESVSALAGLDIGHLRGRRQLTFDQYVELLKENLRCLVPTKNRDVDVERYLPL
VTRTASRPRLALRRVVDYHRQYEWV

TaG - signal peptidase II (LSPA)

From nucleotide 10909 to 11421, size(aa): 171

09710262-11000

See
B1
cont

2290.00075

MNTPSLTNWPARLGYLLAVGGAWFAADQVTQMARDGAKRPVAVFDSWWHFHYVENRAGAFGLFSS
FGEEWRMPFFVYVGAICIVLLIGYYFYTPPTMKLQRWLSLATMIGGALGNYVDRVRLRYVVDVSVWHVG
DRFYWPSFNADTAVVVGAAALMILESFRPREPQQLSPG

TaH - cytochrome P450 hydroxylase (cP450)

From nucleotide 11473 to 12897, size(aa): 475

MGTSEPVEPDHALSKPPPAPVGAQALPRGPAMPGIAQLMMLFLRPTEFLDRCAARYGDTFTLKIPGTPF
FIQTSDPALIEVIFKGDPLFLGGKANNGLKPVVGENSLVLDGKRHRRDRKLIPTFLGERMHAYGSKI
RDIVNAALDRWPVGKRFVHEETQOIMLEVILRVIFGLEDARTIAQFRHHVHQLKLALFLFPNGEGKPA
AEGFARAVGKAFFSLDVFASLKAIDDIYQEIQDRRSQDISGRQDVLSLMMQSHYDDGSMVTPQELRDEL
MTLLMAGHETSATIAAWCVYHLCRHPDAMGKIREIAAHTVDGVLPLAKINELKFLDAVVKETMRITP
VFSLVARVLKEPQTIGGTTYPANVVLSPNYGTHHRADLWGDPKVFRPERFLEERVNPFHYFFPGGGIRK
CIGTSFAYYEMKIFVSETVRRMRFDTRPGYHAKVVRRSNTLAPSQGVPIHVESRLPS

TaI - malonyl CoA [ACP] transacylase (MCT, FabD)

From nucleotide 12938 to 13891, size(aa): 318

MVDSVSKQARRKVFLFSGQGTQSYFMAKELFDTQTGFKRQELLEDEQFKQRLGHSILERYDARAARLD
PLDDVLVSFPAIFMIEHALARLLIDRGIQPDVVGASMGGEVAAAALAGAISVDAVALVAAQAQLFART
PRGGMLAVLHELEACRGFTSVARDGEVAANYPNSNFLAADAAGLGRIQQLSQRSVAFHRLPVRYPFHS
SHLDPLREEYRSRVRADSLTWPRIPMYSCTANRVHDLRSDHFWNVVRAPILQLYDTVLQLEGQGGCDFI
DVGPAASFATIKRILARDSTSRFLPLLSPSPASTGSSMG

TaJ - malonyl CoA [ACP] transacylase (MCT, FabD)

From nucleotide 13909 to 14898, size(aa): 330

MTEAPAPRAPAQVPPPPSSPWALHTRGAASAPVNAKKAALFPGQGSQERGMGAALFDEFDDLTDIADAI
LGYSIKRLCLEDPGKELAQTQFTQPALYVNALSYLKRLREGAEQPAFVAGHSLGEYNALLVAGAFDFE
TGLRLVKRREGELMSGASGGTMAAVVGCDAVAVEQVLRDRQLTSLDIANINSPDQIVVSGPAQDIERARQ
CFVDRGARYVPLNVRAFFHSRYMQPAASEFERFLSQFQYAPLRVCVISNVTGRPYAHDNVVQGLALQLR
SPVQWTATVRYLLEQGVDFEELGPGRVLRITANKRGAPAPATAAPAKWANA

TaK - 3-oxoacyl [ACP] synthase (KAS I, FabB)

From nucleotide 14963 to 16213, size(aa): 417

MSTSPVQELVVSGFGVTSAGQGAASFTSALLEGAAFRVMERPGRQHQANGQTTAHLGAEIASLAVPE
GVTPQLWRSATFSGQAALVTVHEAWNAARLQAVPGHRIGLVVGGTNVQQRDLVLMQDAYRERVPFLR
AAYGSTFMDTDLVGLCTQQFAIHGMSFTVGGASASGLLAVIQAAEAVLSRKVDVCLAVGALMDVSYWE
CQGLRAMGAMGTDRFAREPERACRPFEDRESGDFIFGEACGAVVESAHHARRRGVTPRGILSGWAMQL
DASRGPLSSIERESQVIGAALRHADLAPERVDYVNPHGSGSRQGDALGLALKACGLTHARVNTTKSITG
HGLSSAGAVGLIATLVQLEQGRLESLNLVDPIDSSFRWVGATAEAQSLQNALVLAYGFGGINTAVAVR
RSATES

TaL - enoyl CoA hydratase

From nucleotide 16224 to 17009, size(aa): 262

MQAASPPHRDYQTLRVRFEAQTCFLQLHRPDADNTISRTLIDECQQVLTLCSEHATTVVLEGLPHVFCM
GADFRAIHDRVDDGRREQGNAEQLYRLWLQLATGPYVTVAHVQGGKANAGGLGFVSACDIVLAKAEVQ
FSLSELLFGLFPACVMPFLARRIGIQAHYLTLMTRPIDAAQALSWGLADAVDADSEKLLRIHLRLRLCLS
KPAVTQYKKYASELGGQLLAAMPRAISANEAMFSDRATLEAHRYVETGRLPWES

000111 22201260

Sub
B1
cont

2290.00075

TaM - eno1 CoA hydratase.

From nucleotide 17000 to 17767, size(aa): 256

MGIMTEGTPMAPVVTLEHEVEEGVAQITLVDRNKNMFSEQLVRELITVFGKVNGNERYRAVVL TGYDT
YFALGGTKAGLLSICDGIGSFNVTNFYSLALECDIPVISAMQGHGVGGGFAMGLFADFVVL SRESVYTTN
FMRYGFTPGMGATNIVPKRLGYSLGHELLLNARNYRGADLEKRGVFPVLP RKEVLP HAYELARDLAAK
PRLSLVTLKRHLVRDIRRELPDVIEREIFMHGTFHDDVRRRIEQLFL

TaN - O-methyltransferase (fragment).

From nucleotide 17782 to 19053, size(aa): 423

MLNLINNHAHGYVVTVPVVLACNDAGLFELLRQGPDKDFDLAEALRANRGHLRVAMRMFESLGWVRRD
ADDVYAVTAAAAHRSFPREAQSLFALPMDRYLRGEDGLSLAPWFERSRASWDTDDTLVRELLDGAIT
PLMLALEQRGGGLKEARRLSLWSGGDGRDTCVPEAVQHELAGFFSAQKWTREDAVDAELTPKGAFIFE
RALLFAIVGSYRPM LASMPQLAFGDCDQVFRDEAGHELHLDRTLNVIGSGHQHRKYFAELEKLIITVFD
AENLSAQPRYIADMGC GDGTLAKRVYETVLRHTRGRALDRFPLTLIAADFNEKALEAAGRITLAGLEHV
ALRADVARPDRLIEDLRARGLAEPENTLHRSFLDHD RPVQPPADRAGLHARIPFDSVFVGKAGQEVVPA
EVFHSLEVEHLE

DNA sequence 1-19053

GTCGACGTTGACGTCGCCCCGGTGGCGTGCCGTGTGTCTTCTTCGACGCGGAGGTGCGCGAGGTGGCG
GCGGACGCGCCGGCGCGGGCCGCTGTTGTCGCGTGAGCGCGCGTATGCGCCGGTACTGGCGCTGCGT
GGCCAGCGCTCCATGCTTCGGTGTCTTTTCGCCCCGCTCGCTGATGGCTCCGGTGGAGGTGCGCC
GGTGCAAGGCCCTGCCAGGCACGGTGCCCGCTCTGGTATCAGACGCGCGCACCCGGAGGCCCTGT
CCTGGGAGCGCGTGGGCGCGGTGGGCGAATCCTGCCTCGTGGTGGGTGAACTCCGGAGGGGCCCTG
TCGAGGGCAGCTACGCCCTGGTTCGGTTCGGAGGGGCGGCCCCGCGATGTTGGTGTCTGGGACCCAGG
CTCCGGCCACCTGTGGGACGCTGGCGCGCGGGGCTGGCGGCACCTTCGCGCGCGCCGGGGTGCTGT
CCATGGCCGCGGCCGTCTGTCTCAGGGGCGCTGTGAGACGCGCGGCGGGGGCCGTACCGCCGCG
CCAGAAACGTGATGCGCCGCGAGGCCCTCGCGGTCCGGGCACTGACGCCCCGGGCGCTCGGGACTCG
CTCAGGCGGCTCCGGTGTCTTCGCGCGGTGGAGAACACGAGCTGTTCTCTCGCTGTCCGCCACCCGAC
GGTGAGGGTCCGCTCCACGCCGCGGAGGCCACGCGCGTGGACTGCGCCAGGTCCGAGAGCAGGGA
GCCCCGACGCGCGCAGGTGGAAGCCGGTGGTCCACATGCCCTCCAGCTCGCCGAACACGGTGCAGCAG
CTCGTCCGGGGCCCTTGCGTTCTCGTTCGATGGCGCGCGCAGGCGCACCATGCCGCTACGAAGTTCCTG
CACCAGCATGAGCGTGTGGGGTCTTGGAGATGACCTCCGCGAAGCTGAAGTTGCCGCCACCCGGGGC
GCCACTCGCTTCGATGAGCTGCAGGTCTTTCGCAAGGTTCGCGCACCGTGGGGTCTTCTGGAAGTA
CCACTGGCGATCTGCGCGCGCGCTGGGTGAGCAAGTCAATTCAGCATGAGGCTCGCTTGTCTGCTG
ACCTCGCGGAGGTAGGCCTCCAGATGGGGGEGTAGACCGCGCGCCGGAACCTCGGCGGAGGCGCGG
GGAAGCTGCTCGCTCCAGGGCAGCGCGCGGGCCAGGGCGCGTGAGAAGCGGGACAGCTCGAGCGCTC
TGGATGCGGGGCACCAAGGCGCGGAACGAGTCATCCGCCATCTTCAGCTCGAGCCGCGTTCGATG
GGGTGCTTGCCCATGTCTCTCTCATGGTGTCTGATGACGGTGGCCGCGTCTTCGCGTCCAGCACGC
CCCAGACGACGGCGTCATCCACCGCCTGCTGCAGGTCTTTCGCGACAGCTTCTTCTGCCGTCCCCA
CAGCATCAGGTGCAGGCCGTAGCCGAAGTCGGAGGGCCACGGGGGTGGGAGAGAAGCGCGTCAATGTC
CGCCTTCAGGTCCACCACCCACTGGCCGCGGGTGCCAGCAGCTTGTCTCTGATGCCCCGGCGTCCG
AGGAACGCCATGCGCCGGGCGCCCTGGAAGTCTCTCTCGTACCCAGGACTGCTTGTCTGACGTTCT
TCGCCTTGAGCAGCTCGAACGAGCCAGCCCCAGTGAGAAGCCGATGGCCTGCTGGCGCGTGAGCG
TGGTGGCGTGACAGGTAGTTGCGCAGCTCGAACTCGCTCTGCTGGGCGGGGAGGCTCTTCATCCACT
CAGCAGCTCCACCAAGTTGCCCTTGAGCAGGAGACTCGTGAAGCGCATCGCGGTGACGTCCTCCACG
ACGACCTCCAGCAGCGTGGAGGTCTCCGACAGGCGCAGGTATTCGTA CTGAAGCCCTCGGCGACCT
GCGTGCGGACGGCGTTCTCCAGCAGCTCTGCGACGCGGGCTTGAAGTCGGCCAGGCCCTGCGGAA
GGTTGGCCGGGTCCGCAAGCTGCGGGTTCGATGCCAAGGCGCTCCAGCACCAGGCCAGCACCTTCTT
CTGATTGTCTGTCAGCTTCGCCTTGTCTGGCCTTGTCCACCAGGCCGCTCCATGATTTCCACCGCGGTGG
TGCCCTTCTTGACGAGGTGCGGAAGGACGGGCCCCAGCAGCGCTTCCAGCAACTGGCCCCAGTTGGG
CCTTCACCGTCGCGGGTCCAGCAGCTCCACGGTGTATGCCAGGCCGCGGAGAGCGCCTGCTCATG
GGACTTCACCTTGCACGCGACCTGGATGCGCGCGGCACGGGACGGGAGAAAGCTGAGCTGGTA
GTCGTGGTGAGGGACACCCGGGCGGACAGGCCCGCTTGGCGCTGGTCTTCAACGCGAGCAGCTC

Country	Year	Value	Unit
Algeria	1970	1.00	1000
Algeria	1971	1.00	1000
Algeria	1972	1.00	1000
Algeria	1973	1.00	1000
Algeria	1974	1.00	1000
Algeria	1975	1.00	1000
Algeria	1976	1.00	1000
Algeria	1977	1.00	1000
Algeria	1978	1.00	1000
Algeria	1979	1.00	1000
Algeria	1980	1.00	1000
Algeria	1981	1.00	1000
Algeria	1982	1.00	1000
Algeria	1983	1.00	1000
Algeria	1984	1.00	1000
Algeria	1985	1.00	1000
Algeria	1986	1.00	1000
Algeria	1987	1.00	1000
Algeria	1988	1.00	1000
Algeria	1989	1.00	1000
Algeria	1990	1.00	1000
Algeria	1991	1.00	1000
Algeria	1992	1.00	1000
Algeria	1993	1.00	1000
Algeria	1994	1.00	1000
Algeria	1995	1.00	1000
Algeria	1996	1.00	1000
Algeria	1997	1.00	1000
Algeria	1998	1.00	1000
Algeria	1999	1.00	1000
Algeria	2000	1.00	1000
Algeria	2001	1.00	1000
Algeria	2002	1.00	1000
Algeria	2003	1.00	1000
Algeria	2004	1.00	1000
Algeria	2005	1.00	1000
Algeria	2006	1.00	1000
Algeria	2007	1.00	1000
Algeria	2008	1.00	1000
Algeria	2009	1.00	1000
Algeria	2010	1.00	1000
Algeria	2011	1.00	1000
Algeria	2012	1.00	1000
Algeria	2013	1.00	1000
Algeria	2014	1.00	1000
Algeria	2015	1.00	1000
Algeria	2016	1.00	1000
Algeria	2017	1.00	1000
Algeria	2018	1.00	1000
Algeria	2019	1.00	1000
Algeria	2020	1.00	1000
Algeria	2021	1.00	1000
Algeria	2022	1.00	1000
Algeria	2023	1.00	1000
Algeria	2024	1.00	1000
Algeria	2025	1.00	1000
Algeria	2026	1.00	1000
Algeria	2027	1.00	1000
Algeria	2028	1.00	1000
Algeria	2029	1.00	1000
Algeria	2030	1.00	1000
Algeria	2031	1.00	1000
Algeria	2032	1.00	1000
Algeria	2033	1.00	1000
Algeria	2034	1.00	1000
Algeria	2035	1.00	1000
Algeria	2036	1.00	1000
Algeria	2037	1.00	1000
Algeria	2038	1.00	1000
Algeria	2039	1.00	1000
Algeria	2040	1.00	1000
Algeria	2041	1.00	1000
Algeria	2042	1.00	1000
Algeria	2043	1.00	1000
Algeria	2044	1.00	1000
Algeria	2045	1.00	1000
Algeria	2046	1.00	1000
Algeria	2047	1.00	1000
Algeria	2048	1.00	1000
Algeria	2049	1.00	1000
Algeria	2050	1.00	1000
Algeria	2051	1.00	1000
Algeria	2052	1.00	1000
Algeria	2053	1.00	1000
Algeria	2054	1.00	1000
Algeria	2055	1.00	1000
Algeria	2056	1.00	1000
Algeria	2057	1.00	1000

Sub
B1
cont

2290.00075

CCGCCGGGTGCGGGATTTCGGGGTGTCTCTTCCAATCCCTGTGACTATCTGCGGGTGGGGGACGCGGTG
CGCATCATCGAAGGGGCCCTGACAGGTCTGGAAGGAAGTCTGGTGACGAGCAAGAGCCAACCTCCGG
TTCATTGTCTCCGTGGGGCTGCTACAGCGCTCGGTGTCCGTGGAGGTGAGCGCCGAGCAACTGGAAAC
CGATCACCGACTGATTTCGCGGACATCCCCCTTCCATTCTTCATCACCCCGACCCGACGCAAGGCTTC
AGGGACCGGTGAGTCGTTTCATGGACAAGAGAATTATTTTCGACATCGTCACCAGCAGTGTTCGGGAG
GTGGTACCCGAACCTCGAATCACATCCGTTTCGAGCCGGAGGATGACCTGGTTCGGACTGGGCGCGAAC
TCGCTCGACCGCGCCGAAATCGTCAACCTCACGCTGGAGAAGCTGGCGCTCAACATCCCCCGGGTGC
AGCTGATTGACGCGAAGACCAATTGGCGGGCTGGTGGACGTCCTTCACGCGAGGCTGTGAGGCGAAG
CCATGGGGCCCGGTTCGGGATTGAAGCCATGAATGCCTACTGTGGCATCGCCAGGTTGGATGTGTTGCA
GCTGGCGACCCGACCCGTGGCCTGGACACCTCCCGCTTCGCGAACCTGCTCATGGAGGAGAAGACCGTC
CCGCTCCCCTATGAGGACCCCTGTACCTACGGCGTGAATGCCGCCCGGCCCATCCTGGACCAGTTGA
CCGCGGCGGAACGGGACAGCATTCGAGCTGCTGGTGGCTTGCACGGAGTCTCTGTTTCGACTTCGGCA
AGGCCATGAGCACCTACCTGCAACAGCACCTGGGGCTGAGCCGCAACTGCCCGCTCATCGAGCTCA
AGAGCGCCTGCTACTCCGGGGTCCCGGGCTGCAGATGGCCGTCAACTTCATCCTGTCCGGCGTGTG
GCCGGGGGCAAGGCCCTGGTGGTGGCCTCCGACCTGTTCGCGCTTCTCCATCGCCGAAGGGGGAGA
TGCCCTCCGAGGACTGGTCTTTCGCGGAGCCGAGCTCGGGTCCGGGCGCGGTGGCCATGCTGGT
GAGCGACACGCCCCGGGTGTTCCGGTTCGACGTGGGGGCGAACGGCTACTACGGCTACGAGGTGAT
GGATACCTGCCGCCCGGTGGCGGACAGCGAAGCGGGAGACGCGGACCTGTGCTCTCTCGTACCT
GGACTGCTGTGAGAACGCCTTCCGGGAGTACACCCGCCCGCTCCCGCGCGCAACTACGCGGAGAG
CTTCGGCTACCTCGCCTTCCACACGCCGTTTGGCGGCATGGTGAAGGGCGCCACCGCACGATGATG
CGAAGTTCTCCGGCAAGAACCGCGGGGACATCGAAGCGGACTTCCAGCGCGAGTGGCCCCGGG
CTGACCTACTGCCAGCGCTGGGGAACATCATGGCGCGACGATGGCGCTCTCGCTCCTCGCCGAC
ATCGACACCGCGACTTCGCCACCGCGAAGCGGATTGGCTGCTTCTCGTATGGCTCGGGGTGACGCT
CGGAGTTCTTCAGCGCGCTGGTGACGGAGGAAGGGCAGCAGCGCGAGCGCCCTGGGGCTGGGA
GAAGCGCTGGGGCGCCGGCAGCAGCTCTTCATGCCGGATTACGACGCGCTGCTGAAGGGGAACGGC
CTGGTGCCTTCGGGACCCGGAACGCCGAGCTGGATTTCGGTGTGCTCGGCAGCATCCGGCCGGGC
GGGTGGGGCAGGCCCTTGCTCTTCTTGTTCGCGCATTCGTGACTTCCATCGCGACTACCAATGGATT
CCTAGCCTCGGGGCTTCGAGCAAGCCATGTCCAGCGTAGCGAGCGCGCTCCCGTTCGACGGCCCGTG
ACAGCGCGGTGAGCCGCGGCTGCGAATCACCCCGAGCATGTGCGGCCAGACGTCCTTGTTCGCCGG
GCAGATTGGCGACTGGGCATGGGACACCGTTCAGCCGCTGTGTGGCACGGACGTGCTGACCGCGAC
CAACGCCTCAGGCGCGCCACCTACCTGGCCTTCTATTACTTCCGCATCCGGGGGACGCCCGCGCTG
CATCCCGCGCGCTGCGCTTCGGCGACACGCTGGACGTCACGTGGAAGGCGTACAACCTTCGGCAGC
GAATCCGTCCTGACGGTGACCGCATCTGCAAGACGGCGGAGGGCGCGCTCCGGAGGGCGGATGCC
TTCGGCCATGAAGAGCTGTACGAGCAGCCCCAGCCAGGCGCATCTACCGGAGACCTTCAACCGG
TGGATCACCGCTCGGACGGCAAGTTCGAACGAGAGCCTGATCAAGTCTCGCCCGTGGGGTTCCAG
TACGCACACCTGCCGCTCTTGGCGGACGAATACTCGCCGCGCGGGCCTATGGGGACGCGCGGGCG
CGGGGCACCTTTCACGATGTGGACTCCGCGGAGTACCGGCTGACCGTGGACCGCTTCCCGCTGCGCT
ACGCGGTGGACGTCATCCGGGACGTCATGGGGTGGGGCTCATCTACTTCGCGTCTGATTTCTCGAT
GGTGGACTGGGCCATCTGGCAGCTGGCGAGGCAACAGGACGACGAGCAGGCGCTTCTGTGCGG
CGTGGTCTGGACACGCAACTGTGCTTCTCGGCAACGCGCGCTGGACACCACTTCGACATCGAC
GTGCAGCACTGGGAGCGGGTGGGCGGCGGGGAAGAGCTGTTCAACGTGAAGATGCGCGAGGGCGC
GCAGGGCCGGGACATCGCCGTGGCGACGGTCAAGGTGCGCTTCGACGCGGCTTCGGAAGGAGGCGG
CCGTGGGTGAGCCGATGACAGACGAACAAATCCGCGGAGTCTGTCACCAAGTCCATCGTGCCTCC
TGCCCCGCGTGCCTCCAACGAGATTGCGGGCCACTTGAACCTCCGCGAGCTGGGCGCGGACTCCGT
GGACCGGTTCGAGATTCTCACGTCCATCTGTGACAGCTCGCGGTGCAGAAGACGCCACTGGCGAA
GTTCCCGCATCCGCAACATCGACGCGCTGGTGGCGTTCCTGGCCGTTGAGGTGCGGGTGGCTG
AGCGGTTCCCGCGGAGTTCGGCATCGAGGCCATCAACGCCCTACGGCGCGCGCCCTCCATTCCGG
TGTTGACTTGTTCGGGGCCGGCGGCTGGACCCCGAAGCGATTCTCCAACCTGATGATGCAGGAGC
GCGGCGTCCGCTGCCGTTTCGAGGACCCGTCACCAACGCGGTCAATGCGGCGCGGCCATCCTGG
ACGCGATGTCGCCCGAGGCCCCGGGAGCGCATCGAGCTCTGGTCACTTCGAGCGAGTCCGGCGTGG
ACTTCAGCAAGTCCATCTCTCGTATGCGCACAGGACCTGGGGCTGAGCCGCCACTGCCGTTCT
GGAGGTGAAGCAGGCGTGTACGCCGCCACCGGAGCGCTCCAGCTAGCGCTGGCTACATCGCGTC
GGCGGTGTACCCGGGGGCCAAGGCCCTGGTGATTGCCACGACGTCAGCTGGTGGACGAGAGCGG
TCTGTACTCCGAGCCGGCGATGGGACCGGCGCGCTCGCGTGTGCTGGGCGACGAGCCGCGCGT
GATGAAGATGGACCTGGGAGCGTTTCGGCAACTACAGCTACGACGTTTCGACACCGCGCGGCCCTC
GCCGGAGATTGATATCGGCGACGTGGACCGGTGCTCTTCACTGACCTGGACTGCCTCAAGCACAGC
TTCGCCGCGTATGGCCGCCGGGTGGACGGTGTGACTTCGTCTCGACGTTTCGACTACCTGGCGATGC
ACAGCCGTTCCGCCGACTGGTGAAGCCGGGCCACCGCAAGATGATGCGCGAGCTACCCCGTGGC
ACGTGGAGCAAAATCGAAGCGGACTTCGGCGCGCGCTGAAGCGCTCACTGACGATACCCGCTGG
TCGGGAACCTGTGCTCCGGCTCCGTGTACCTGAGCCTGTGCACCATCATCGACACCATCAAGCCCGA
GCGGTCCGCTCGGGTGGGAATGTTCTCTATGGGTGGGTTGCTGCTCGGAGTCTTTCAGCGGCGTE
ATCGGCCCGGAGTCCGTGTCCGCGCTAGCTGGGTGGACATCGGTTGGCCACCTCCGGGGGCGCCGC
CAGCTCACGTTTCGACCAATATGTGCAATTGCTGAAAGAGAACCTTCGCTGTCTGGTTCCAACGAAGA
ACCGGGACGTGGACGTGGAGCGCTACCTCCCGCTGGTGACGCGGACGGCGAGCCGCCCGCGCATGC

00011222-11000

Sub
B1
CMT

AGCGGCCGGGCGCTCAGCATCAGGCCAACGGGCGAGACGAGCGGCCACCTGGGGGGCGGAAATCGCCT
 CGCTGGCCGTGCCCGAAGGCGTCACCCCACTGTGGCGCTCGGCCACGTTTCGGGGCAGGCCCG
 ACTGGTGACCGTCCACGAGGCCCTGGAACGCGCGCGCCTCCAGGCCGTCCCCGGACACCGGATTGG
 ATTGGTGGTGGGGGGCA CCAACGTGCAGCAGCGGACCTGGTGCTGATGCAAGACGCCTATCGCGA
 GCGGGTGCCCTTTCTGCGGGCGGCCTACGGGTGACCTTCATGGACACCGACCTCGTGGGCCTCTGC
 ACGCAGCAGTTCGCCATCCACGGGATGTCCTTACGGGTGGGAGGCGCATCGGCCAGTGGCCTGCTG
 GCGGTTCATCCAGGCCGCGGAGGCGGTGCTCTCAAGAAGGGTGGACGTTTGCATCGCCGTGGGGGCG
 CTGATGGACGTCTCTACTGGAATGCCAGGGCCTGCGGGCCATGGGCGCGATGGGCACCGACCGG
 TTCGCGCGGGAGCCGGAGCGGTGCTTGGCGGCCCTTCGACCGGGAGAGTGATGGCTTCATCTTTGGAG
 AGGCGTGCGGCGCCGTGGTGTTGAGTCTGCGGAGCACGCTCGGCGACGCGGGGTGACTCCTCGCG
 GCATCCTGTGCGGCTGGGCCATGCAGTTGGACGCGAGCGCGGCCGTTGTCTGCCATCGAAGGGG
 AGTCGCAGGTGATTGGGGCTGCGCTGCGGCACGCGGACCTCGCGCCGGAGCGGGTGGACTACGTGA
 ATCCTCACGGCAGCGGTTGCGGTGAGGGGGATGCCATCGAGCTGGGGGCTTGAAGGCGTGCGGCC
 TGACGCACGCCCCGGGTCAACACCAAGGTCATCACGGGCGATGGCCTGTCTCGGCGGGTGCCGT
 GGGGCTCATCGCCACGCTGGTCCAGTTGGAGCAGGGCCGGGTGCACCCGTCTTGAACCTGGTGGAG
 CCGATTGATTATCGTTCCGCTGGGTGGGGCCACCGCGGAGGCCAGTCCCTCCAGAACGCGCTGG
 TGCTCGCCTACGGCTTCGGCGGCATCAACACCGCTGTGCGCGTGCGCCGGAGCGCCACGGAGAGCT
 GACACGCCCATGCAAGCCGCTTCCCTCCGCACCGCGACTACCAGACGCTCCGGGTCCGCTTCGAGG
 CGCAGACCTGTTTTCTCCAGCTCCACCGGCCGGATGCGGACAACACCATCAGCCGCACGCTGATTGA
 CGAGTGCCAGCAGGTGCTCACGTTATCTGAGGAGCACGCCACACGGTGGTGCTCGAAGGCCTGCC
 ACACGTGTTCTGCATGGGCGCGGATTTTCGAGCCATCCACGACCGGGTCGACGACGCGCCGCGGA
 GCAAGGCAACGCGGAGCAGCTGTACCGGCTGTGGCTGCAACTGGCGACAGGCCCTTACGTCAGCGT
 CGCCATGTGCAAGGGCAAGGCCAAGCGGGCGGCTGGGCTTCGTCGCCGCGTGCGACATCGTGCT
 GGCAAAGGCGGAGGTCCAGTTCACTCTCCGAGCTGCTGTTCCGGGCTGTTCCCGCCTGCGTGATG
 CCGTTCCTCGCCCGGCGAATCGGCATCCAGCGGGCGCACTACCTGACGCTGATGACGCGGCCCATCG
 ACGCGGCCAGGCGCTGAGCTGGGGGTTGGCGGACGCGGTGGACGCCGATAGCGAGAAGCTGTTGC
 GGCTCCACTTGCGCAGGCTGCGGTGCCTGTGCAAGCCAGCGGTGACCCAGTACAAGAAGTACGCC
 CCGAGCTGGGCGGCCAGCTGCTCGCGGCCATGCCCGGCCATCTCCGCCAATGAGGCGATGTTCTC
 CGACCGCGCCACGCTGGAAGCCATCCATCGCTACGTGGAGACAGGCCGACTCCCATGGGAATCATG
 ACGGAAGGAACGCCAATGGCGCCGGTGGTCCAGCTCCATGAGGTGGAGGAGGGGGTGGCGCAGAT
 CACCCTGGTGGATCGCGAGAACAAGAATCTTTCAGCGAGCAGCTCGTGCGCGAGCTCATCACCGT
 GTTCGGCAAGGTGAATGGAACGAGCGCTACCGCGCGGTGGTGCTCACCGGCTACGACACCTACTT
 CGCGCTCGGCGGGACCAAGGCCGGCCTGCTGTCCATCTGCGACGGCATCGGCTCCTTCAACGCTCAC
 AACTTCTACAGCCTCGCGCTGGAGTGCACATCCCGGTGATTTCGCCCATGCGAGGCGATGGCTAG
 GCGCGGGGTTCCGCGATGGGGCTGTTCCGGGACTTCGTGGTCTGAGCCGGGAGAGCGTCTACACGA
 CGAACTTCATGCGCTACGGCTTCACGCCGGGGATGGGCGCCACGTACATCGTGCCGAAGCGGCTGG
 GGTACTCGCTCGGGCATGAGCTCCTGCTCAACGCCAGGAACCTACCGCGGCGCCGACCTGGAGAAGC
 GGGGCGTGCTTTTCCGGTGTGTCGCGCGCAAGGAAGTCTTGCCCCACGCCCTACGAGATTGCGAGGGA
 CCTGGCCGCGAAACCTCGGCTGTGCTCGTGACGCTCAAGCGGCACCTGGTTCGCGACATCCGCCGA
 GAGCTTCGGACGTCATCGAGCGTGAGCTGGAGATGCACGGCATCACCTTCCATCAGACGACGCTG
 AGGAGGCGCATCGAGCAGCTGTTCTCTGAGGCGCGCCCTATGTTGAACCTGATCAACAACCACGC
 ACACGGTTATGTGGTCACGCCCGTGGTCTGCGCTGCAACGACGCTGGCCTGTTGAACTCCTGCGG
 CAGGGACCGAAGGACTTCGACCGGTTGGCGGAGGCAATGCGTGCCAACCGGGGACATCTGCGCGTC
 GCGATGAGGATGTTGCAATCGCTCGGCTGGGTTGCGCGCGACGCGGATGACGTGTACGGGTGACG
 GCGGCGGCGGCGCGCATCGGTCTTCCCCCGCGAGGCGCAGTGCCTCTTCGCGCTGCCATGGACC
 GGTACCTGCGCGGGGAGGACGGCCTGTCCCTGGCGCGGTGGTTCGAGCGCTCTCGGGCGCTGGG
 ATACCGATGACACGCTGGTGCGCGAGCTGCTCGACGGCGCCATCATCACCGCGCTGATGCTCGCGCT
 GGAGCAGCGTGGGGGCCCTCAAGGAGGCGAGGCGTCTGTCCGACCTGTGGTCCGGGGGGGATGGAA
 GGGACACGTGCGTCCCCGAGGCCGTCCAACACGAGCTGCGCGGTTCTTCTCCGCGCAGAAAGTGA
 CGCGTGAGGACGCGCTCGACGCGGAGCTCACGCCCAAGGGCGCCTTCATCTTCGAGCGGGCATTGC
 TCTTCGCCATCGTGGCTCGTACCGGCCGATGCTGGCCAGCATGCCGAGCTGCTCTTCGCTGACTG
 CGACCAGGTCTTCGGGCGGGACGAAGCGGGCCAGCACTGCACCTGGACCGGAACCTCAACGTGAT
 TGGGAGCGGCCACCGACCGGAAGTACTTCGCGGAGCTGGAGAAGCTCATCATCACCGTCTTCGA
 TGCCGGAACCTGTGCGCACAGCCGCGCTACATCGCGGACATGGGGTGGGTGACGGCACGCTCCT
 GAAGCGGGTGTATGAAACGGTGCTTCGGCACACGCGGCGGGGAAGGGCGCTCGACCGGTTTCGCT
 CACGCTCATCGCCGCGGACTTCAACGAGAAGGCGCTCGAAGCCGCTGGGCGGACGCTGGCCGGGT
 GGAGCACGTTGCTTGGCGCGGACGCTGGCGCGGCGGACCGTCTCATCGAGGACCTGCGGGCGCG
 CGGGCTAGCCGAGCCTGAGAATACGCTGCACATCCGCTCGTTCTCGACCAACGACCGTCCCTACG
 CCTCCCGCGGACAGGGCGGGGCTCCACGCCGATTCCGTTGATTTCGGTGTTCGTGGGCAAGGCG
 GGCCAGGAGGTGGTTCGGGCGGAGGTGTTCCACAGCCTGGTGGAGCACCTCGAG